Rezolute, Inc.
NCM: RZLTLive Quote
About Rezolute, Inc.
Healthcare
Biotechnology
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
📊 Fundamental Analysis
Rezolute, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -74.0%, which indicates that capital utilization is currently under pressure.
At a current price of $3.64, RZLT currently sits at the 25th percentile of its 52-week range (Range: $1.07 - $11.46).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$375.54M
Trailing P/E
--
Forward P/E
-5.32
Beta (5Y)
0.66
52W High
$11.46
52W Low
$1.07
Avg Volume
2.94M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App